IBT
International Biotechnology Trust Portfolio holdings
AUM
$297M
This Quarter Return
+13.9%
1 Year Return
+17.25%
3 Year Return
+11.14%
5 Year Return
+79.35%
10 Year Return
–
AUM
$284M
AUM Growth
+$284M
(+10%)
Cap. Flow
+$34.2M
Cap. Flow
% of AUM
12.07%
Top 10 Holdings %
Top 10 Hldgs %
45.99%
Holding
71
New
15
Increased
14
Reduced
11
Closed
6
Top Buys
| 1 |
Nektar Therapeutics
NKTR
|
$12.6M |
| 2 |
SAGE
Sage Therapeutics
SAGE
|
$5.68M |
| 3 |
SHPG
Shire pic
SHPG
|
$4.84M |
| 4 |
STML
Stemline Therapeutics, Inc.
STML
|
$4.84M |
| 5 |
Exelixis
EXEL
|
$4.74M |
Top Sells
| 1 |
XLRN
Acceleron Pharma Inc.
XLRN
|
$5.75M |
| 2 |
Sarepta Therapeutics
SRPT
|
$5.23M |
| 3 |
CALA
Calithera Biosciences, Inc
CALA
|
$2.95M |
| 4 |
ADMS
Adamas Pharmaceuticals, Inc.
ADMS
|
$2.54M |
| 5 |
ALXN
Alexion Pharmaceuticals Inc
ALXN
|
$2.36M |
Sector Composition
| 1 | Healthcare | 91.95% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
Biogen
BIIB
$19.4B
| $20.7M | 7.3% | 65,008 -6,500 | -9% | -$2.07M |
|
|
CELG
2
DELISTED
Celgene Corp
CELG
| $19.8M | 6.99% | 190,022 +9,500 | +5% | +$992K |
|
3
Regeneron Pharmaceuticals
REGN
$61.5B
| $15.4M | 5.41% | 40,830 | – | – |
|
|
4
Nektar Therapeutics
NKTR
$568M
| $12.6M | 4.44% | +211,000 | New | +$12.6M |
|
|
5
Exelixis
EXEL
$10.1B
| $12.5M | 4.4% | 410,334 +156,000 | +61% | +$4.74M |
|
6
Vertex Pharmaceuticals
VRTX
$100B
| $11.3M | 3.99% | 75,422 -13,300 | -15% | -$1.99M |
|
|
ADMS
7
DELISTED
Adamas Pharmaceuticals, Inc.
ADMS
| $10.7M | 3.76% | 315,000 -75,000 | -19% | -$2.54M |
|
8
Acadia Pharmaceuticals
ACAD
$4.38B
| $10M | 3.54% | 333,773 +93,000 | +39% | +$2.8M |
|
9
Gilead Sciences
GILD
$140B
| $8.8M | 3.1% | 122,784 | – | – |
|
|
ALXN
10
DELISTED
Alexion Pharmaceuticals Inc
ALXN
| $8.67M | 3.05% | 72,441 -19,700 | -21% | -$2.36M |
|
|
SAGE
11
DELISTED
Sage Therapeutics
SAGE
| $8.48M | 2.99% | 51,496 +34,500 | +203% | +$5.68M |
|
|
ENTL
12
DELISTED
Entellus Medical, Inc. Common Stock
ENTL
| $8.33M | 2.94% | 341,468 | – | – |
|
|
STML
13
DELISTED
Stemline Therapeutics, Inc.
STML
| $7.69M | 2.71% | 492,930 +310,000 | +169% | +$4.84M |
|
14
Incyte
INCY
$16.5B
| $6.91M | 2.44% | 72,975 -16,000 | -18% | -$1.52M |
|
|
TSRO
15
DELISTED
TESARO, Inc.
TSRO
| $6.41M | 2.26% | 77,300 +42,300 | +121% | +$3.51M |
|
16
Amgen
AMGN
$155B
| $6.28M | 2.21% | 36,104 | – | – |
|
|
ARRY
17
DELISTED
Array Biopharma Inc
ARRY
| $6.11M | 2.15% | 477,500 +230,000 | +93% | +$2.94M |
|
18
BioMarin Pharmaceuticals
BMRN
$11.2B
| $6.1M | 2.15% | 68,384 | – | – |
|
19
Halozyme
HALO
$8.56B
| $5.72M | 2.02% | 282,633 | – | – |
|
|
CLVS
20
DELISTED
Clovis Oncology, Inc.
CLVS
| $5.17M | 1.82% | 76,000 +20,000 | +36% | +$1.36M |
|
|
SHPG
21
DELISTED
Shire pic
SHPG
| $4.84M | 1.71% | +31,200 | New | +$4.84M |
|
22
Alnylam Pharmaceuticals
ALNY
$58.5B
| $4.68M | 1.65% | 36,800 -4,500 | -11% | -$572K |
|
|
PRTK
23
DELISTED
Paratek Pharmaceuticals, Inc.
PRTK
| $4.54M | 1.6% | 253,500 +51,500 | +25% | +$922K |
|
24
Ligand Pharmaceuticals
LGND
$3.15B
| $3.97M | 1.4% | 29,000 | – | – |
|
|
BLUE
25
DELISTED
bluebird bio
BLUE
| $3.56M | 1.26% | 20,000 | – | – |
|